查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞治疗技术的全球市场：按产品类型、按工艺、按细胞类型、按最终用户、按地区 - 预测至 2028 年
市场调查报告书
商品编码
1323873

细胞治疗技术的全球市场：按产品类型、按工艺、按细胞类型、按最终用户、按地区 - 预测至 2028 年

Cell Therapy Technologies Market by Product, Process, Cell type, End User, Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 236 Pages | 订单完成后即时交付

价格
简介目录

全球细胞治疗技术市场规模预计将从 2023 年的 42 亿美元增至 2028 年的 78 亿美元，预测期内復合年增长率为 13.3%。

政府对细胞研究的投资增加、慢性病和传染病患病率上升、肿瘤相关细胞治疗临床试验大幅下降以及细胞治疗生产设施的 GMP 认证增加等因素正在推动市场增长。这将产生积极影响。

按流程划分，全球细胞治疗技术市场分为细胞加工、细胞保存、分配/处理和流程监控/质量控制。2022年的市场份额由细胞加工领域主导。细胞处理技术的进步可能会对市场增长产生积极影响。

按最终用户划分，市场分为生物製药和生物技术公司、CRO 和 CMO、研究机构和细胞库。2022年，生物製药和生物技术公司细分市场占据细胞治疗技术市场的最大份额。由于多种因素，包括主要市场参与者增加细胞治疗生产设施以及增加对细胞治疗研究活动的投资，该细分市场占据了市场主导份额。

预计亚太地区的细胞治疗技术市场在预测期内将以显着的复合年增长率增长。该地区增长的主要驱动力是政府对细胞研究的投资增加。由于疫苗开发研究经费的增加和疾病概况的变化，中国、印度和日本对细胞治疗设备和产品的需求不断增加，这将支持亚太地区的市场增长。我是。此外，慢性病和传染病患病率的增加、老年人口的增加以及政府改善医疗基础设施的举措预计将对市场增长产生积极影响。

该报告考察了全球细胞治疗技术市场，并提供了市场概况，包括按产品类型、工艺、细胞类型、最终用户、地区以及参与市场的公司概况划分的趋势。

目录

第 1 章 简介

第二章研究方法论

第三章执行摘要

第 4 章重要注意事项

第五章市场概况

  • 介绍
  • 市场动态
  • 影响客户业务的趋势/中断
  • 参考价格模型分析
  • 技术分析
  • 价值链分析
  • 供应链分析
  • 细胞治疗技术市场生态系统分析
  • 2022-2023年主要会议和活动
  • 监管分析
  • 波特五力分析
  • 专利分析
  • 主要利益相关者和采购标准

第六章细胞治疗技术市场（按产品）

  • 介绍
  • 培养基、血清和试剂
  • 细胞工程产品
  • 细胞培养容器
  • 细胞治疗仪
  • 系统与软件
  • 其他

第七章细胞治疗技术市场（按流程）

  • 介绍
  • 细胞处理
  • 细胞储存、分配和处理
  • 过程监控和质量控制

第八章细胞治疗技术市场（按细胞类型）

  • 介绍
  • T细胞
  • 干细胞
  • 其他

第九章细胞治疗技术市场（按最终用户）

  • 介绍
  • 生物製药和生物技术公司
  • 合同研究官、首席营销官
  • 研究机构和细胞库

第10章细胞治疗技术市场（按地区）

  • 介绍
  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第十一章竞争格局

第十二章公司简介

  • 主要进入者
    • THERMO FISHER SCIENTIFIC, INC.
    • MERCK KGAA
    • DANAHER CORPORATION
    • LONZA GROUP
    • SARTORIUS AG
    • TERUMO BCT, INC.
    • BECTON DICKINSON AND COMPANY
    • FRESENIUS SE & CO. KGAA
    • AVANTOR, INC.
    • BIO-TECHNE
    • CORNING INCORPORATED
    • FUJIFILM IRVINE SCIENTIFIC
    • MAXCYTE, INC.
  • 其他公司
    • WERUM IT SOLUTIONS
    • ROOSTERBIO, INC.
    • SIRION BIOTECH
    • TRAKCEL
    • L7 INFORMATICS, INC.
    • MILTENYI BIOTEC B.V. & CO. KG
    • STEMCELL TECHNOLOGIES
    • GPI IBERIA（FORMERLY HEMASOFT）
    • MAK-SYSTEM
    • ORGANABIO
    • IXCELLS BIOTECHNOLOGIES
    • WILSON WOLF

第十三章附录

简介目录
Product Code: BT 6823

The global cell therapy technologies market size is projected to reach USD 7.8 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 13.3 % during the forecast period. Factors such as increasing government investments in cell-based research, rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, increasing GMP certification for cell therapy production facilities are likely to have positive impact on the market growth.

"The process segment held the dominant share in the cell therapy technologies market"

Based on process, the global cell therapy technologies market is segmented into cell processing, cell preservation, distribution & handling, process monitoring & quality control. The cell processing segment held a dominant share in the market in 2022. Advancement in cell processing techniques is likely to have positive impact on the growth of the market.

"Biopharmaceutical and biotechnology companies segment accounted for the largest share of the application segment in 2022."

Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CROS & CMOS, research institutes & cell banks. In 2022, the biopharmaceutical and biotechnology companies segment accounted for the largest share of the cell therapy technologies market. The segment held the dominant share in the market owing to various factors such as the emphasis on increase in number of cell therapy manufacturing facilities by key market players and rising investment in research activities of cell therapy.

"Asia Pacific region is likely to grow at a faster pace."

The cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing government investments in cell-based research. The increasing demand for cell therapy instruments and products from China, India, and Japan due to the rising research funding for vaccine development and changing disease profiles supports market growth in the Asia Pacific. Furthermore, increasing incidence of chronic and infectious diseases, the rising geriatric population, and government initiatives for healthcare infrastructural improvements are some of the elements anticipated to account for positive impact on the market growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70%, and Demand Side - 30%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

List of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • Merck KGaA (Germany)
  • Danaher Corporation (US)
  • Lonza Group (Switzerland)
  • Sartorius AG(Germany)
  • Terumo Bct, Inc Corporation (Japan) (Terumo BCT is part of Terumo Corporation)
  • Becton, Dickinson & Company (US)
  • Fresenius Se & co. KGaA (Germany)
  • Avantor Inc (US)
  • Bio-Techne (US)
  • Corning Incorporated (US)
  • Fujifilm Irvine Scientific (Japan)
  • Maxcyte Inc. (US)
  • Werum Software & Systems AG (Part of Korber AG) (Germany)
  • Roosterbio Inc. (US)
  • Sirion Biotech Gmbh (Germany)
  • Trakcel (UK)
  • L 7 Informatics Inc. (US)
  • Miltenyi Biotech (Germany)
  • Steamcell Technologies Inc. (Canada)
  • GPI Iberia (Formerly Hemasoft) (Spain)
  • CodexThemes (France)
  • Organabio LLC. (US)
  • Ixcells Biotechnologies (US)
  • Wilson Wolf 2019 Manufacturing Corporation (US)

Research Coverage:

This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments, such as product, process,cell type, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing government investments in cell-based research, Rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, Increasing GMP certification for cell therapy production facilities), restraints ( High cost of cell-based research and low success rate), opportunities (Emergence of iPSC as alternatives to ESCs, Increased focus on personalized medicine, Increasing public-private partnerships for development of cell therapies, Emerging Asian markets), and challenges (Survival for small players and new entrants)are influencing the growth of cell therapy technologies market.
  • Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the Cell therapy technologies market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the cell therapy technologies market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Becton, Dickinson, and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany), and among others in the cell therapy technologies market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 RESEARCH LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
  • 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER)
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH RATE ASSUMPTIONS
    • FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS, 2023-2028
    • FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
    • FIGURE 16 INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES
  • 4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2022)
    • FIGURE 17 T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2023 VS. 2028
    • FIGURE 18 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028
  • 4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY END USER, 2022 (USD MILLION)
    • FIGURE 19 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022
  • 4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing government investments in cell-based research
    • TABLE 4 NIH FUNDING FOR CELL-BASED RESEARCH, 2019-2022 (USD MILLION)
      • 5.2.1.2 Rising incidence of chronic and infectious diseases
      • 5.2.1.3 Large number of oncology-related cell therapy clinical trials
    • FIGURE 22 CANCER CELL THERAPY PIPELINE, 2021-2022
      • 5.2.1.4 Increasing GMP certifications for cell therapy production facilities
    • TABLE 5 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of cell-based research and low success rate
    • TABLE 6 COST OF CELL THERAPY EQUIPMENT
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emergence of iPSCs as alternatives to ESCs
      • 5.2.3.2 Increased focus on personalized medicine
      • 5.2.3.3 Increasing partnerships for development of cell therapies
      • 5.2.3.4 Emerging Asian markets
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Survival of small players and new entrants
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS
  • 5.4 INDICATIVE PRICING MODEL ANALYSIS
    • TABLE 7 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET
    • FIGURE 26 ECOSYSTEM ANALYSIS
    • TABLE 8 SUPPLY CHAIN ECOSYSTEM
  • 5.9 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 9 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.10 REGULATORY ANALYSIS
    • 5.10.1 REGULATORY LANDSCAPE FOR CELL THERAPIES
    • TABLE 10 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES
    • TABLE 11 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES
    • TABLE 12 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES
    • TABLE 13 ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES
    • 5.10.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 19 CELL THERAPY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 DEGREE OF COMPETITION
  • 5.12 PATENT ANALYSIS
    • FIGURE 27 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013-JULY 2023
    • TABLE 20 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS
    • 5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS
    • FIGURE 29 KEY BUYING CRITERIA FOR END USERS

6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 21 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 MEDIA, SERA, AND REAGENTS
    • 6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
    • TABLE 22 MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 23 NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 CELL ENGINEERING PRODUCTS
    • 6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH
    • TABLE 26 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY
    • TABLE 27 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 CELL CULTURE VESSELS
    • 6.4.1 WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS
    • TABLE 31 CELL CULTURE VESSELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 32 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 CELL THERAPY EQUIPMENT
    • TABLE 35 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 36 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 37 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021-2028 (USD MILLION)
    • TABLE 38 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 39 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.5.1 CELL PROCESSING EQUIPMENT
      • 6.5.1.1 Cell processing equipment to dominate market
    • TABLE 40 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.5.2 SINGLE-USE EQUIPMENT
      • 6.5.2.1 Benefits of single-use equipment to ensure end-user demand
    • TABLE 44 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.5.3 OTHER EQUIPMENT
    • TABLE 48 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.6 SYSTEMS & SOFTWARE
    • 6.6.1 NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND
    • TABLE 52 SYSTEMS & SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.7 OTHER PRODUCTS
    • TABLE 56 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS

  • 7.1 INTRODUCTION
    • TABLE 60 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
  • 7.2 CELL PROCESSING
    • 7.2.1 CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028
    • TABLE 61 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING
    • 7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH
    • TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 PROCESS MONITORING & QUALITY CONTROL
    • 7.4.1 NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION
    • TABLE 69 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)

8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE

  • 8.1 INTRODUCTION
    • TABLE 73 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
  • 8.2 T CELLS
    • 8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
    • TABLE 74 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 75 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 STEM CELLS
    • 8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
    • TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 79 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER CELLS
    • TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION)

9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET
    • TABLE 87 CELL THERAPY TECHNOLOGIES MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 CROS & CMOS
    • 9.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
    • TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 RESEARCH INSTITUTES & CELL BANKS
    • 9.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH
    • TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION)

10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 99 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
    • TABLE 100 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 104 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Increasing R&D activities to support market growth
    • TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 109 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 110 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments
    • TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 113 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 114 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: RECESSION IMPACT
    • TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 119 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 120 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 121 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Germany to hold largest share of European market
    • TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 124 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 125 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 126 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Favorable funding and investment scenario to drive market
    • TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 130 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Availability of government and private support to drive market
    • TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 133 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 134 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 135 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Initiatives favoring cell and gene therapy development to support market growth
    • TABLE 137 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 138 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 139 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 140 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 141 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing funding from private and public organizations to aid market growth
    • TABLE 142 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 143 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 145 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 147 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 148 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 150 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 152 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 153 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 154 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 156 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 157 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing cell therapy-based trials to support market growth
    • TABLE 158 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 159 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 160 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 161 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 162 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Rising geriatric population and growing disease prevalence to drive market
    • TABLE 163 JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022
    • TABLE 164 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 165 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 166 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 167 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Favorable government regulations to support market growth
    • TABLE 169 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 170 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 172 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 173 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 174 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 175 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 176 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 177 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET
    • 10.5.2 LATIN AMERICA: RECESSION IMPACT
    • TABLE 179 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 180 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 181 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 183 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET
    • 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 184 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 185 MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 187 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 188 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS
    • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
    • TABLE 189 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX, 2022
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
  • 11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
    • 11.6.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
    • TABLE 190 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
    • 11.6.2 COMPANY PROCESS FOOTPRINT (25 COMPANIES)
    • TABLE 191 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS
    • 11.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
    • TABLE 192 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
  • 11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
    • 11.7.1 PROGRESSIVE COMPANIES
    • 11.7.2 STARTING BLOCKS
    • 11.7.3 RESPONSIVE COMPANIES
    • 11.7.4 DYNAMIC COMPANIES
    • FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
  • 11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    • TABLE 193 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 194 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
  • 11.9 COMPETITIVE SCENARIO AND TRENDS
    • 11.9.1 PRODUCT LAUNCHES
    • TABLE 195 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2020-APRIL 2023
    • 11.9.2 DEALS
    • TABLE 196 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2020-APRIL 2023
    • 11.9.3 OTHER DEVELOPMENTS
    • TABLE 197 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2020-APRIL 2023

12 COMPANY PROFILES

  • 12.1 KEY MARKET PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 12.1.1 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 198 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.2 MERCK KGAA
    • TABLE 199 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 12.1.3 DANAHER CORPORATION
    • TABLE 200 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.4 LONZA GROUP
    • TABLE 201 LONZA GROUP: BUSINESS OVERVIEW
    • FIGURE 40 LONZA GROUP: COMPANY SNAPSHOT (2022)
    • 12.1.5 SARTORIUS AG
    • TABLE 202 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2022)
    • 12.1.6 TERUMO BCT, INC.
    • TABLE 203 TERUMO BCT, INC: BUSINESS OVERVIEW
    • FIGURE 42 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.7 BECTON DICKINSON AND COMPANY
    • TABLE 204 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 43 BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 12.1.8 FRESENIUS SE & CO. KGAA
    • TABLE 205 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
    • FIGURE 44 FRESENIUS SE & CO: COMPANY SNAPSHOT (2022)
    • 12.1.9 AVANTOR, INC.
    • TABLE 206 AVANTOR, INC.: BUSINESS OVERVIEW
    • FIGURE 45 AVANTOR, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.10 BIO-TECHNE
    • TABLE 207 BIO-TECHNE: BUSINESS OVERVIEW
    • FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022)
    • 12.1.11 CORNING INCORPORATED
    • TABLE 208 CORNING INCORPORATED: BUSINESS OVERVIEW
    • FIGURE 47 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
    • 12.1.12 FUJIFILM IRVINE SCIENTIFIC
    • TABLE 209 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 48 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022)
    • 12.1.13 MAXCYTE, INC.
    • TABLE 210 MAXCYTE, INC.: BUSINESS OVERVIEW
    • FIGURE 49 MAXCYTE, INC.: COMPANY SNAPSHOT (2022)
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 12.2 OTHER PLAYERS
    • 12.2.1 WERUM IT SOLUTIONS
    • 12.2.2 ROOSTERBIO, INC.
    • 12.2.3 SIRION BIOTECH
    • 12.2.4 TRAKCEL
    • 12.2.5 L7 INFORMATICS, INC.
    • 12.2.6 MILTENYI BIOTEC B.V. & CO. KG
    • 12.2.7 STEMCELL TECHNOLOGIES
    • 12.2.8 GPI IBERIA (FORMERLY HEMASOFT)
    • 12.2.9 MAK-SYSTEM
    • 12.2.10 ORGANABIO
    • 12.2.11 IXCELLS BIOTECHNOLOGIES
    • 12.2.12 WILSON WOLF

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS